Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Parenting and CAH - 21-hydroxylase Deficiency

Description of Parental Projects, Pregnancies and Pregnancy Outcomes in Patients With a Classic Form of 21-hydroxylase Deficiency

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Congenital adrenal hyperplasia (CAH) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis enzymes. 21-hydroxylase deficiency (21OHD), related to mutations of the CYP21A2 gene, is involved in 90 to 95% of CAH cases. Depending on the severity of the mutations of this gene, there are severe forms known as "classic" (FC), with neonatal onset, and moderate forms known as "non-classic" (FNC), with onset later in childhood or after puberty. The classic form includes the salt-wasting form and the pure virilizing form, depending on the degree of aldosterone deficiency. The sexuality and fertility of women with classic 21OHD deficiency are impaired by several factors such as disruption of the gonadotropic axis due to overproduction of androgens and progesterone by the adrenal glands, and mechanical and psychological factors related to genital surgery. The fertility of these women improves over time, largely due to earlier treatment of CAH, improved therapeutic compliance and surgical advances in genital reconstruction leading to an increase in the percentage of patients who are sexually active. However, there is little data available, and even less on the course of pregnancy, its complications and its outcomes.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged 18 or over - Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically - Patients who have been informed and do not object to participating in the research Who Should NOT Join This Trial: - Patients who do not speak French - Patients who are not affiliated to a social security scheme or who are not entitled to it - Patients under legal protection, or under guardianship or trusteeship. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged 18 or over * Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically * Patients who have been informed and do not object to participating in the research Exclusion Criteria: * Patients who do not speak French * Patients who are not affiliated to a social security scheme or who are not entitled to it * Patients under legal protection, or under guardianship or trusteeship.

Treatments Being Tested

OTHER

phone questionnaire

the investigator calls the patient and asks her questions about her parental project and her pregnancies

Locations (4)

Hospices Civiles de Lyon - Hôpital Femme Mère Enfant, Service Endocrinologie
Bron, France
AP-HP Hôpital Bicêtre, Service Endocrinologie
Le Kremlin-Bicêtre, France
Service d'endocrinologie, Hôpital Pitié Salpêtrière
Paris, France
Service d'endocrinologie, Hôpital Saint Antoine
Paris, France